Get your studies off the ground fast with Elixirgen Scientific’s iPSC services including differentiation services, assay services, and R&D. Some of our assay services include high content imaging, electrophysiological assay, transcriptome analysis, RT-qPCR, and drug screening. Our proprietary technology enables iPSC differentiation with a faster turnaround time than any other preclinical service provider in the world.
Let's discuss how iPSC services can benefit your project.
Whether you’re an experienced iPSC researcher or just getting started, our scientists are here to answer your questions and provide ongoing support. All iPSC services begin with a free consultation to define the scope of the project, including the desired differentiated cell type, the production scale (1-50 million viable cells), and desired characterization assays (ICC, MEA, etc.).
If you don’t currently have an iPSC line, we can also provide assistance in obtaining iPSC lines from iPSC banks or gene-editing service providers. Consultations are free, so request a consultation today to discuss your project requirements. iPSC lines Elixirgen recognize are listed here.
Upon receiving your frozen or live iPSC line(s), we expand or adapt the cells in optimal conditions for growth and differentiation. For our transcription factor-based differentiation platform, we use feeder-free, single-cell passaging conditions for iPSC expansion/adaptation for best results.
During iPSC expansion, we produce working and back-up stocks of the iPSC line along with a certificate of analysis to verify pluripotency and karyotype upon request.
Our proprietary iPSC differentiation technology produces functional, highly pure populations neurons in as little as 1 week without leaving a genetic footprint.
Our standard differentiated cell types include a variety of neuronal subtypes (GABAergic, dopaminergic, cholinergic, or sensory) and astrocytes but we can also use our iPSC expertise to develop a custom differentiation strategy for generating your desired cell or tissue type.
Prior to shipping, we conduct a variety of quality control checks to ensure that differentiated cells are free from contaminants, express lineage-specific markers, and have optimal post-thaw viability.
We also offer a variety of optional in-house assay services, including microelectrode array (MEA), neurite outgrowth assay, and calcium transient assay, if in depth functional characterization is desired.
Differentiated cells are shipped either live or cryopreserved depending on preference and are supplied with media supplements and detailed instructions for optimal cell maintenance.
Ready to order? Easily access our profile through a scientific supplier to conveniently order with Elixirgen Scientific.
At Elixirgen Scientific, we are passionate about innovation. It is important that we provide our products and services with convenience to your lab. We are proud to have joined ScienceExchange and Scientist.com that provide an efficient ordering platform for your lab to access our iPSC-derived technology.
ALS Disease Study
Healthy control and ALS patient-derived iPSCs were differentiated into cholinergic neurons. The cells were fixed at day 10 from iPSCs and stained by TUBB3 (Green) and TDP-43 (Red).
MEA (multi-electrode array) assay
Your drug candidates could be tested on MEA plate after iPSC differentiation. Healthy control and disease patient iPSC line derived cells could be plated onto the same MEA plate to test quantitative property changes with drug candidates.
Neurite length analysis
Our fast differentiation enables quicker and quantitative comparison between healthy and patient or treated and non-treated cultures.
Global transcriptome analysis
Our bioinformatic team enables unbiased analyses with transcriptome datasets from RNA-sequence and microarray. If you would like to capture global difference between patient and healthy/isogenic control or non-treated or treated cultures, let's discuss with us for designing experiments.
Antibody validation
Antibodies used for fluorescent imaging often have undetermined specificity. Elixirgen Scientific can use mRNA transfection and iPSCs to generate proper positive controls to validate antibody specificity.
New differentiation protocol development
Elixirgen Scientific proprietary transcriptome database and plasmid library enable the systematic and fast iPSC differentiation protocol development.
Whether you know exactly what you need or you want to learn more about how Elixirgen Scientific can help you, our team of experts is ready to assist. Start with our free project design consultation.
The price for the differentiation of one hPSC (iPS or ES) line starts at just $1,000.
If you do not already have an established iPSC line, you can find patient iPSC lines in your interest here. Contact us for you to learn more about sourcing iPSC lines and differentiation.
Sending biomaterials is always challenging. However, Elixirgen Scientific has a lot of experience in cross border logistics for cells and biological materials. Our knowledge and expertise will navigate you to properly prepare your iPSCs to ship. We use dry ice shipment in the US and liquid nitrogen dry shipper internationally to ship cryopreserved cells. We can also accept live hPSC lines to speed up an entire process and lower total fees.
We do not currently offer services for reprogramming cells into iPSCs. However, we can work with our partners to take care of this reprogramming services from fibroblast or PBMC.
| Disease | Mutant genes (# of iPSC lines) | Number of total patient iPSC lines |
|---|---|---|
| ABCA1 heterozygous | ABC1 (2) | 2 |
| Abetalipoproteinemia | MTP (2) | 2 |
| Acromesomelic dysplasia | NPR2 (1) | 1 |
| Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) | 1 | |
| Adrenoleukodystrophy (ALD) | 1 | |
| Adult-onset Still’s disease (AOSD) | 1 | |
| Age-related macular degeneration (AMD) | 121 | |
| Aicardi syndrome | 1 | |
| Alexander disease | GFAP (3) | 6 |
| Allergic granulomatous angiitis | 1 | |
| Alzheimer's disease (AD) | APOE (10), APOE4 (3), APP (4), C9ORF (1), CD33 (2), MAPT (2), PSEN1 (14), PSEN2 (1), TBK1 (1), TREM2 (3) | 180 |
| Alzheimer's disease (AD) (Gene-edited) | APP (6), PSEN1 (8) | 14 |
| Alzheimer's disease (AD) (familial) | APP (3), APPV7171 (4), PSEN1 (1), PSEN2 (1) | 11 |
| Amyotrophic lateral sclerosis (ALS) | ASYMPTOMATIC C9ORF72 CARRIER (1), C9ORF72 (46), FIG4 (1), FUS (3), SETX (1), SETX, SOD1 (1), SOD1 (36), SOD1 > D90A (1), TARDBP (5), VCP (1) | 532 |
| Anemia (phenotype) | 1 | |
| Angelman syndrome | UBE3A (2) | 10 |
| Aplastic anemia | 3 | |
| Arrhythmogenic right ventricular cardiomyopathy | 2 | |
| Arteriolosclerosis | 2 | |
| Associated pulmonary arterial hypertension | 18 | |
| Ataxia-telangiectasia | 3 | |
| Atrial fibrillation | 14 | |
| Atrial tachycardia | 1 | |
| Autism spectrum disorder (ASD) | 110 | |
| Autoimmune hemolytic anemia (AHA) / Idiopathic warm (AHA) | 1 | |
| Bardet-biedl syndrome | 22 | |
| Batten disease (cln3) | CLN3 (23) | 23 |
| Batten disease (cln6) | 8 | |
| Behçet’s disease | 2 | |
| Beta thalassemia | HBB (2) | 2 |
| Bethlem myopathy | 2 | |
| Bilateral frontoparietal polymicrogyria | GPR56 (1) | 1 |
| Bipolar disorder | 30 | |
| Blinding eye disease | 18 | |
| Borderline NASH (fatty liver disease) | 2 | |
| Breast cancer | BRCA1 (3) | 3 |
| Brugada syndrome | 6 | |
| Buerger’s disease | 1 | |
| Cardiomyopathy | 48 | |
| Carpal tunnel syndrome | 18 | |
| Catecholaminergic polymorphic ventricular tachycardia | RYR2 (2) | 2 |
| Ccanavan Disease | ASPA (1) | 1 |
| Cchoroideremia (CHM) | CHM (1), NGLY1 (1) | 4 |
| Cerebral creatine deficiency syndrome 1 (CCDS1) | SLC6A8 (1) | 1 |
| Cerebral palsy (CP) | 19 | |
| Cerebrovascular disease | 4 | |
| Ceroid lipofuscinosis | CHM (1), CLN2 (1) | 2 |
| Charcot-Marie-Tooth disease | FIG4 (1), MFN2 (10), MPZ (2), PMP22 (7), VCP (1) | 22 |
| Chromosome 16p11.2 deletion syndrome | 5 | |
| Chronic inflammatory demyelinating polyneuropathy (CIDP) | 2 | |
| Chronic myeloid leukemia | 1 | |
| Congenital disorder of deglycosylation (CDDG) | CFTR (1) | 1 |
| Congenital heart block | 2 | |
| Congenital ichthyosis / Ichthyosis syndrome | 1 | |
| Congenital insensitivity to pain with anhidrosis (CIPA) | 2 | |
| Congenital myasthenic syndrome | GFPT1 (1) | 7 |
| Congenital myopathy | MTM11 (1) | 1 |
| Control | C9ORF72 (5), CCR5 (1), GFAP CORRECTED (2), HBB (1), HD (5), HNF1A (1), MECP2 (2), NGN2 (2), SNCA (1), SOD1 > D90A CORRECTED (1), TAF1 VARIANT CORRECTED (4) | 25 |
| Coronary artery disease | 43 | |
| Corticobasal degeneration (CBD） | 1 | |
| Crohn's disease | 3 | |
| Crow‐Fukase syndrome | 2 | |
| Cystic Fibrosis (CF) | DMPK (1) | 1 |
| Cystinosis | 1 | |
| DMD | DMD (5) | 5 |
| DMRV / GNE myopathy | 2 | |
| Danon disease | 1 | |
| Definite NASH (fatty liver disease) | 32 | |
| Diabetes | HNF1A (2) | 3 |
| Diabetes mellitus | 60 | |
| Diabetes mellitus type II | 12 | |
| Diabetes type I | 21 | |
| Diabetes type II | 95 | |
| Diabetes type unknown | 4 | |
| Diabetic retinopathy (DR) | 32 | |
| Diamond-Blackfan anemia | 1 | |
| Dilated cardiomyopathy (DCM) | 303 | |
| Distal Myopathy | 3 | |
| Down syndrome | 47,XX,+21 (4), 47,XY,+21 (3) | 8 |
| Dravet syndrome | SCN1A (11) | 11 |
| Drug-induced liver injury (DILI) | 4 | |
| Duchenne Muscular dystrophy (DMD) | DMD (1) | 2 |
| Dystrophia myotonica 1 (DM1) | DMPK (1) | 1 |
| Ehlers-Danlos syndrome | COL3A1 (1) | 2 |
| Eosinophilic granulomatosis with polyangiitis (EGPA) | 1 | |
| Eosinophilic sinusitis | 1 | |
| Epidermolysis bullosa | 1 | |
| Epilepsy | ALG13 (1), GABRA1 (1), KCNC1 (1), PCDH19 (2), SCN2A (1) | 57 |
| Fabry disease | 3 | |
| Facioscapulohumeral muscular dystrophy 1 (FSHD1) | LRIF1 (1) | 6 |
| Familial Mediterranean fever | 1 | |
| Fatty liver disease - steatosis (not NASH) | 2 | |
| Focal cortical dysplasia (FCD) | 2 | |
| Focal segmental glomerulosclerosis | 20 | |
| Fragile X syndrome | FMR1 (4) | 4 |
| Friedreich ataxia 1 (FRDA) | FXN (2) | 2 |
| Frontotemporal degeneration | C9ORF72 (4), GRN (4), MAPT (10), PGRN (2), VCP (1) | 25 |
| Frontotemporal dementia (FTD) | C9ORF72 (6), MAPT (15) | 30 |
| Frontotemporal lobar degeneration (FTLD) | 2 | |
| GM1-gangliosidosis | 1 | |
| Galactosialidosis | 1 | |
| Gaucher disease | GBA (1) | 2 |
| Giant cell arteritis (GCA) | 2 | |
| Glaucoma | 20 | |
| Glut1 deficiency syndrome 1 (Glut1DS1) | SLC2A1 (1) | 1 |
| Glycogen storage disease / GSD type V (muscle glycogen phosphorylase deficiency) | 1 | |
| Glycosylphosphatidylinositol(GPI) anchor deficiency | 3 | |
| Granulomatosis with polyangiitis (GPA) | 1 | |
| Hemiconvulsion-hemiplegia-epilepsy syndrome | 2 | |
| Hemimegalencephaly | 1 | |
| Hepatitis C (HCV) | 91 | |
| Hereditary dystonia | 1 | |
| Homozygous familial hypercholesterolemia | LDLR (6) | 6 |
| Hunter syndrome | 2 | |
| Huntington's disease (HD) | HD (14), HTT (36), IT15 (1), SMN1 (1) | 58 |
| Hurler syndrome | IDUA (1) | 1 |
| Hutchinson-gilford progeria syndrome (HGPS) | 2 | |
| Hyperalphalipoproteinemia | SR-BI (2) | 2 |
| Hypertrophic cardiomyopathy | TNNT2 (1) | 83 |
| Idiopathic aplastic anemia | 1 | |
| Idiopathic pulmonary arterial hypertension | 16 | |
| Idiopathic pulmonary fibrosis (IPF) | 182 | |
| Idiopathic thrombocytopenic purpura | 1 | |
| IgG4-related disease | 1 | |
| IgG4-related thyroid disease | 1 | |
| Inappropriate sinus tachycardia | 1 | |
| Infantile neuroaxonal dystrophy (INAD) | PLA2G6 (5) | 5 |
| Intellectual disability (ID) | 60 | |
| Interstitial lung disease | 1 | |
| Isaacs syndrome | 1 | |
| Isogenic control | 3 | |
| Kearns-sayre syndrome (KSS) | 1 | |
| Keratoconus | 2 | |
| Krabbe disease | GALC (1) | 1 |
| Landau-Kleffner syndrome | 1 | |
| Left ventricular hypertrophy | 15 | |
| Left ventricular non-compaction cardiomyopathy | 10 | |
| Lennox-Gastaut syndrome (LGS) | 2 | |
| Lesch-nyhan syndrome (LNS) | HPRT1 (1) | 1 |
| Lewy body dementia | 8 | |
| Lewy body dementia (LBD) | 1 | |
| Limb-girdle muscular dystrophy | DYSF (5) | 5 |
| Limb-girdle muscular dystrophy (LGMD2b) | DYSF (15) | 15 |
| Lissencephaly | DCX (1) | 1 |
| Long QT syndrome | 3 | |
| Long QT syndrome (familial) | 13 | |
| Long QT syndrome 1 (LQT1) | 3 | |
| Long QT syndrome 2 (LQT2) | KCNH2 (1) | 1 |
| Long QT syndrome 3 (LQT3) | SCN5A (1) | 1 |
| MELAS | 1 | |
| Malignant rheumatoid arthritis (MRA) | 1 | |
| Mental illness | DISC1 EXON 8 WILD-TYPE (2) | 2 |
| Mental retardation | CHAMP1 (2), SYNGAP1 (1) | 3 |
| Mesial temporal lobe epilepsy with hippocampal sclerosis | 2 | |
| Microscopic polyangiitis (MPA) | 1 | |
| Migraine disorder | MAJOR CHR17 AMPLIFCATION; MINOR CHR7 DELETION (1) | 28 |
| Mild left ventricular hypertrophy | 1 | |
| Miller-dieker lissencephaly syndrome (MDLS) | 1 | |
| Mitochondrial diseases | 1 | |
| Mixed Connective-Tissue Disease (MCTD) | 1 | |
| Monogenic diabetes | 13 | |
| Mortor dominant | 1 | |
| Moyamoya disease | 3 | |
| Mucopolysaccharidosis (MPS) | SGSH (1) | 3 |
| Multifocal motor neuropathy (MMN) | 1 | |
| Multiple sclerosis (MS) | 4 | |
| Multiple system atrophy (MSA) | 6 | |
| Muro disease (Kii ALS/PDC) | 3 | |
| Muscular dystrophy | DMD (5), LAMA2 (1), POMT2 (1) | 9 |
| Myasthenia Gravis (MG) | 1 | |
| Myocardial infarction | 18 | |
| Myoclonic epilepsy | CHD2 (1) | 1 |
| Myotonic dystrophy | CNBP (4), DMPK (1) | 9 |
| Nescav syndrome | KIF1A (5) | 6 |
| Neurodegeneration with brain iron accumulation 5 (NBIA5) | WDR45 (1) | 1 |
| Neurodevelopmental disorder | DHPS (1) | 1 |
| Neuroferritinopathy | 1 | |
| Neurofibromatosis type1 (NF1) | 1 | |
| Neurofibromatosis type2 (NF2) | 1 | |
| Neuromyelitis Optica | 4 | |
| Neuromyelitis Optica Spectrum Disorders (NMOSD) | 1 | |
| Neuronal migration disorder | PIK3R2 (1) | 3 |
| Neuropathy | GARS (2), SCN9A (6) | 39 |
| Niemann-pick disease | NPC1 (1), SMPD1 (3) | 5 |
| Non-als motor neurone disease | 1 | |
| Ohtahara syndrome | STXBP1 (1) | 1 |
| Ornithine transcarbamylase deficiency (OTCD) | 1 | |
| Osteogenesis imperfecta type iv (OI4) | COL1A2 (1) | 1 |
| PACS1 (Schuurs-Hoeijmakers) syndrome | PACS1 (2) | 2 |
| Pain agnosia | SCN11A (2) | 2 |
| Parkinsonism | GBA (2), LRRK2 (6), MAPT (1), PARK2 (4), PINK1 (1), SNCA (3) | 26 |
| Parkinson’s disease (PD) | GBA (18), LRRK2 (8), SNCA (9) | 99 |
| Paroxysmal nocturnal hemoglobinuria (PNH) | 1 | |
| Pemphigoid (including epidermolysis bullosa acquisita) | 2 | |
| Pemphigus | 2 | |
| Periodic paralysis | 1 | |
| Phenylketonuria | PAH PAH (1) | 2 |
| Pick's disease | 1 | |
| Pitt-hopkins syndrome (PTHS) | TCF4 (1) | 1 |
| Polyarteritis nodosa (PAN) | 2 | |
| Polymicrogyria | 1 | |
| Pompe’s disease (adult type) | 1 | |
| Primary antiphospholipid syndrome | 2 | |
| Primary erythromelalgia | SCN9A (2) | 4 |
| Primary immunodeficiency syndrome | 3 | |
| Primary lateral sclerosis (PLS) | 7 | |
| Primary open angle (POAG) | 20 | |
| Primary progressive aphasia (PPA) | 1 | |
| Progressive multifocal leukoencephalopathy (PML) | 1 | |
| Progressive supranuclea palsy (PSP) | 1 | |
| Prolonged QT interval | 6 | |
| Pulmonary arterial hypertension | ALK1 (2), BMPR2 (4) | 6 |
| Pulmonary atresia | 1 | |
| Pustular psoriasis | 1 | |
| Pyogenic sterile arthritis / Pyoderma gangrenosum and acne syndrome | 1 | |
| Rasmussen encephalitis | 2 | |
| Relapsing polychondritis (RP) | 1 | |
| Resolved systolic anterior motion | 1 | |
| Restrictive cardiomyopathy | 1 | |
| Retinitis pigmentosa | 5 | |
| Rett syndrome | FOXG1 (5), MECP2 (6), SHANK3 (1) | 15 |
| Right ventricular outflow tract premature ventricular contractions | 2 | |
| Ring chromosome 20 syndrome | 2 | |
| Sanfilippo syndrome / MPS IIIC (acetyl-CoA:heparan-α-Ｄ-glucosaminide N-acetyltransferase deficiency) | 1 | |
| Schizophrenia | 4 | |
| Semantic Dementia | 2 | |
| Severe combined immunodeficiency | ADA (2) | 2 |
| Sickle cell anemia | HBB (55) | 55 |
| Sjögren’s syndrome | 1 | |
| Skeletal displasia | 4 | |
| Small atrial septal defect | 1 | |
| Smith-magenis syndrome (SMS) | 1 | |
| Spinal muscular atrophy | SMN1 (14) | 18 |
| Spinal-Bulbar Muscular Atrophy (SBMA) | 10 | |
| Spinocerebellar Degeneration | 14 | |
| Spinocerebellar ataxia type 1 | 2 | |
| Spinocerebellar ataxia type 3 | ATXN3 (4) | 4 |
| Spondylometaphyseal displasia | 2 | |
| Stevens-Johnson syndrome (SJS) | 1 | |
| Sturge-Weber syndrome | 1 | |
| Subacute sclerosing panencephalitis (SSPE) | 2 | |
| Syringomyelia | 1 | |
| Systemic amyloidosis | 2 | |
| TNF receptor-associated periodic syndrome | 1 | |
| Takayasu arteritis | 3 | |
| Tangier disease | ABC1 (2), ABCA1 (4) | 6 |
| Tay-sachs disease (TSD) | HEXA (1) | 1 |
| Thrombotic thrombocytopenic purpura (TTP) | 1 | |
| Tricuspid atresia | 1 | |
| Tuberous sclerosis | TSC2 (2) | 3 |
| Ventricular tachycardia | 5 | |
| Vertebrobasilar insufficiency(VBI) | 1 | |
| Vici syndrome (VICIS) | EPG5 (1) | 1 |
| Werner syndrome | 1 | |
| West syndrome | 1 | |
| Wilson’s disease | 4 | |
| Wolfram syndrome | 1 | |
| Wolman disease | 1 | |
| X-linked creatine transporter deficiency | 1 | |
| X-linked dystonia Parkinsonism | TAF1 VARIANT (34) | 34 |
| Xeroderma pigmentosum | 2 |
